Page 69 - Genentech News Today

– Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date –– Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study –– These data will be presented as an or...

– Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone –– The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations –– These new data are being pre...

Neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab compared with placebo plus chemotherapy continued to show a clinically meaningful improvement in event-free survival in patients with high-risk, early-stage triple-negative breast cancer.

The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer enrolled in the phase 3 KEYNOTE-756 trial.

In previously treated patients with locally advanced unresectable or metastatic HER2-positive breast cancer, tucatinib and trastuzumab emtansine improved progression-free survival vs T-DM1 alone.

Almost all postmenopausal patients aged 50-69 years with stage I hormone receptor (HR)-positive breast cancer and low scores on a common genetic test who opted out of adjuvant radiotherapy were disease free five years after surgery, according to results from the IDEA clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.

The Switzerland market ended marginally up on Tuesday after swinging between gains and losses, after a somewhat lackluster session..

BOTHELL, Wash.--(BUSINESS WIRE)--Dec 6, 2023--

For patients whose breast cancer converted from lymph node-positive to lymph node-negative disease after neoadjuvant chemotherapy, skipping adjuvant regional nodal irradiation (RNI) did not increase the risk of disease recurrence or death five years after surgery, according to results from the NRG Oncology/NSABP B-51/RTOG 1304 clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.

/PRNewswire/ - Oxford Properties Group ("Oxford"), a leading global real estate investor, developer and manager has officially broken ground on a 165,000...